Clinical Trial Update: Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. [Phase 1, Phase 2]

View source ↗

Summary

Cantargia's Nadunolimab is being studied in combination with gemcitabine and carboplatin for advanced triple-negative breast cancer in Phase 1/Phase 2 trials, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Gemcitabine (Gemcitabine)
• Nadunolimab (nadunolimab)

Snippet

Sponsor: Cantargia AB | Conditions: Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING